Scholar Rock Holding Corp (SRRK) shareholders
Close on Nov 17, 2026Market cap $5.49BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 14,114,029 | 15.00% | 13G (passive) amendment | Dec 31, 2024 |
| Artal International Management S.A. Joint filing with Invus Public Equities, L.P. (17.40%), Invus Public Equities Advisors, LLC (17.40%) and 5 more | 12,834,446 | 17.40% | 13G (passive) amendment | Dec 31, 2023 |
| Invus Public Equities, L.P. Joint filing with Invus Public Equities Advisors, LLC (11.40%), Invus Global Management, LLC (11.40%) and 2 more | 10,825,013 | 11.40% | 13G (passive) amendment | Dec 31, 2024 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (9.90%), RedCo II Master Fund, L.P. (6.90%) | 9,885,124 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Siren, L.L.C. Joint filing with Invus Public Equities, L.P. (8.00%), Invus Public Equities Advisors, LLC (8.00%) and 2 more | 9,575,013 | 8.00% | 13G (passive) amendment | Jun 30, 2026 |
| Srinivas Akkaraju Joint filing with Samsara BioCapital, L.P. (6.60%), Samsara BioCapital GP, LLC (6.60%) | 6,991,553 | 7.20% | 13D (active) amendment | Oct 3, 2025 |
| T. Rowe Price Associates, Inc. | 6,206,044 | 5.40% | 13G (passive) amendment | Mar 31, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (5.60%), Wellington Investment Advisors Holdings LLP (5.60%) and 1 more | 5,759,428 | 5.60% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 4,962,597 | 6.90% | 13G (passive) | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SRRK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 17,995,241 | 14.78% | $989.74M | +752,089 | 0.04% |
| Siren, L.L.C. | 9,575,013 | 7.86% | $526.63M | −1,250,000 | 10.66% |
| BlackRock, Inc. | 9,494,084 | 7.80% | $522.17M | +2,024,791 | 0.01% |
| Samsara BioCapital, LLC | 6,897,652 | 5.66% | $379.37M | – | 31.16% |
| Price T Rowe Associates Inc /Md/ | 6,794,837 | 5.58% | $373.72M | +588,219 | 0.04% |
| Wellington Management Group Llp | 6,727,085 | 5.52% | $369.99M | +9,430 | 0.06% |
| Orbis Allan Gray Ltd | 5,933,533 | 4.87% | $326.34M | +1,753,550 | 1.12% |
| Vanguard Capital Management LLC | 4,767,880 | 3.91% | $262.23M | +876,533 | 0.01% |
| State Street Corp | 4,728,681 | 3.88% | $260.08M | +697,364 | 0.01% |
| Redmile Group, LLC | 4,311,092 | 3.54% | $237.11M | −4,755,529 | 15.92% |
| Norges Bank | 2,769,910 | 2.27% | $152.35M | New | 0.02% |
| Geode Capital Management, LLC | 2,753,787 | 2.26% | $151.49M | +604,751 | 0.01% |
| Massachusetts Financial Services Co /Ma/ | 2,607,348 | 2.14% | $143.39M | New | 0.05% |
| Bellevue Group AG | 2,449,547 | 2.01% | $134.73M | −1,135,026 | 2.83% |
| Jennison Associates LLC | 2,358,587 | 1.94% | $129.72M | −981,905 | 0.08% |
| Jupiter Topco LLC | 2,242,106 | 1.84% | $123.28M | New | 0.05% |
| Hood River Capital Management LLC | 2,224,788 | 1.83% | $122.36M | +175,109 | 0.89% |
| Driehaus Capital Management LLC | 2,205,618 | 1.81% | $121.31M | +285,385 | 0.70% |
| Eventide Asset Management, LLC | 2,111,410 | 1.73% | $116.13M | −85,975 | 1.55% |
| Polar Capital Holdings Plc | 1,878,580 | 1.54% | $103.32M | −105,048 | 0.24% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 306 | 139M | 100.0% | 58 / 129 | 83 / 21 | 25M | 18M |
| Q1 2026 | 274 | 134M | 100.0% | 41 / 113 | 78 / 36 | 24M | 8M |
| Q4 2025 | 274 | 124M | 100.0% | 77 / 95 | 68 / 37 | 24M | 16M |
| Q3 2025 | 241 | 117M | 95.8% | 44 / 93 | 64 / 36 | 17M | 11M |
| Q2 2025 | 235 | 110M | 90.5% | 41 / 92 | 70 / 36 | 12M | 8M |
| Q1 2025 | 231 | 107M | 87.5% | 39 / 88 | 69 / 30 | 11M | 9M |
| Q4 2024 | 224 | 104M | 85.7% | 85 / 69 | 60 / 20 | 29M | 13M |
| Q3 2024 | 161 | 89M | 72.9% | 25 / 55 | 55 / 29 | 27M | 18M |
| Q2 2024 | 166 | 86M | 70.5% | 33 / 69 | 45 / 27 | 12M | 11M |
| Q1 2024 | 161 | 85M | 70.1% | 42 / 51 | 47 / 14 | 9M | 6M |
| Q4 2023 | 133 | 82M | 67.4% | 52 / 65 | 10 / 7 | 29M | 1M |
| Q3 2023 | 89 | 54M | 44.3% | 16 / 51 | 15 / 11 | 6M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
294 funds held SRRK in Q2 2026, 27% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SRRK | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 4,515,375 | 3.71% | $222.61M | 0.23% | May 31, 2026 |
| Vanguard Health Care Fund | 3,859,866 | 3.17% | $182.55M | 0.48% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 3,427,521 | 2.81% | $188.51M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,870,009 | 2.36% | $157.85M | 0.19% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 2,299,437 | 1.89% | $126.47M | 0.86% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,258,236 | 1.85% | $124.20M | 1.16% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,650,449 | 1.36% | $81.37M | 1.55% | May 31, 2026 |
| Eventide Gilead Fund | 1,460,906 | 1.20% | $80.35M | 2.34% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,271,656 | 1.04% | $62.69M | 0.23% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,222,019 | 1.00% | $57.80M | 0.17% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,141,385 | 0.94% | $62.78M | 0.06% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 1,128,752 | 0.93% | $62.08M | 0.07% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 1,118,671 | 0.92% | $55.15M | 0.40% | May 31, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,108,147 | 0.91% | $60.95M | 0.62% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 1,098,284 | 0.90% | $54.15M | 0.22% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David Hallal | Chief Executive Officer, Director | 1,844,034 | 1.51% | Sep 23, 2026 |
| Akshay Vaishnaw | President of R&D, Director | 630,542 | 0.52% | Apr 20, 2026 |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER, Director | 425,561 | 0.35% | Mar 12, 2025 |
| Keith Woods | Chief Operating Officer | 620,055 | 0.51% | Sep 25, 2026 |
| Vikas Sinha | Chief Financial Officer | 619,856 | 0.51% | Apr 20, 2026 |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 98,645 | 0.08% | Feb 25, 2026 |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | 126,012 | 0.10% | Feb 19, 2026 |
| Junlin Ho | GENERAL COUNSEL | 241,545 | 0.20% | Feb 19, 2026 |
| Caryn Parlavecchio | CHRO | 169,087 | 0.14% | Feb 19, 2026 |
| Tracey Sacco | Chief Commercial Officer | 76,250 | 0.06% | Apr 29, 2025 |
| Erin Moore | Interim PFO and PAO | 96,173 | 0.08% | Mar 25, 2025 |
| Edward H. Myles | COO & CFO | 111,345 | 0.09% | Mar 12, 2025 |
| Srinivas Akkaraju | Director | 7,131,508 | 5.86% | Oct 27, 2026 |
| Joshua Reed | Director | 20,466 | 0.02% | Jul 6, 2026 |
| Katie Peng | Director | 34,322 | 0.03% | Jul 6, 2026 |
| Michael Gilman | Director | 59,554 | 0.05% | Jul 6, 2026 |
| Kristina Burow | Director | 2,460,368 | 2.02% | Jul 6, 2026 |
| Jeffrey S. Flier | Director | 27,871 | 0.02% | Jul 6, 2026 |
| Richard Brudnick | Director | 21,896 | 0.02% | Jun 8, 2026 |
| Raymond Debbane | 10% owner | – | – | Feb 6, 2026 |
| Siren, L.L.C. | 10% owner | 10,825,013 | 8.89% | Feb 6, 2026 |
| Invus Global Management, LLC | 10% owner | 9,250,005 | 7.60% | Feb 6, 2026 |
| Invus Public Equities Advisors, LLC | 10% owner | 10,850,154 | 8.91% | Dec 12, 2024 |
| Invus Public Equities, L.P. | 10% owner | – | – | Dec 12, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Srinivas Akkaraju Director | Oct 26, 2026 | Buy | +97,982 | $41.59 | $4.08M | 723,020 |
| Srinivas Akkaraju Director | Oct 26, 2026 | Buy | +48,988 | $41.59 | $2.04M | 6,380,517 |
| Srinivas Akkaraju Director | Oct 23, 2026 | Buy | +1,000 | $41.82 | $41.82K | 625,038 |
| Srinivas Akkaraju Director | Oct 23, 2026 | Buy | +500 | $41.82 | $20.91K | 6,331,529 |
| Srinivas Akkaraju Director | Oct 23, 2026 | Buy | +94,000 | $41.31 | $3.88M | 624,038 |
| Srinivas Akkaraju Director | Oct 23, 2026 | Buy | +47,000 | $41.31 | $1.94M | 6,331,029 |
| Keith Woods Chief Operating Officer | Sep 24, 2026 | Gift | −48,034 | – | – | 572,021 |
| David Hallal Chief Executive Officer, Director | Sep 21, 2026 | Gift | −36,652 | – | – | 1,602,382 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,470 | $54.24 | $79.73K | 27,871 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −15 | $54.88 | $823 | 27,856 |
| Jeffrey S. Flier Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,568 | $53.53 | $83.94K | 29,341 |
| Kristina Burow Director | Jul 1, 2026 | Sale(10b5-1 plan) | −948 | $54.28 | $51.46K | 114,657 |
| Kristina Burow Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,105 | $53.49 | $112.60K | 115,605 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,155 | $54.23 | $62.64K | 59,554 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −1,346 | $53.54 | $72.06K | 60,709 |
| Michael Gilman Director | Jul 1, 2026 | Sale(10b5-1 plan) | −43 | $54.81 | $2.36K | 59,511 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,437 | $54.25 | $132.21K | 34,322 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −21 | $54.96 | $1.15K | 34,301 |
| Katie Peng Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,988 | $53.56 | $160.04K | 36,759 |
| Joshua Reed Director | Jul 1, 2026 | Sale(10b5-1 plan) | −2,105 | $53.50 | $112.62K | 20,466 |
| Joshua Reed Director | Jul 1, 2026 | Sale(10b5-1 plan) | −948 | $54.28 | $51.46K | 19,518 |
| Kristina Burow Director | Jun 4, 2026 | Award | +6,839 | – | – | 117,710 |
| Michael Gilman Director | Jun 4, 2026 | Award | +6,839 | – | – | 62,055 |
| Katie Peng Director | Jun 4, 2026 | Award | +6,839 | – | – | 39,747 |
| Jeffrey S. Flier Director | Jun 4, 2026 | Award | +6,839 | – | – | 30,909 |
| Srinivas Akkaraju Director | Jun 4, 2026 | Award | +6,839 | – | – | 27,971 |
| Richard Brudnick Director | Jun 4, 2026 | Award | +6,839 | – | – | 21,896 |
| Joshua Reed Director | Jun 4, 2026 | Award | +6,839 | – | – | 22,571 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +28,000 | $4.75 | $133.00K | 56,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +7,800 | $26.78 | $208.88K | 28,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +36,000 | $9.11 | $327.96K | 92,871 |
| Kristina Burow Director | Apr 23, 2026 | Option exercise | +18,000 | $8.36 | $150.48K | 110,871 |
| David Hallal Chief Executive Officer, Director | Apr 16, 2026 | Sale | −30,615 | $49.57 | $1.52M | 1,639,034 |
| Keith Woods Chief Operating Officer | Apr 16, 2026 | Sale | −10,220 | $49.57 | $506.61K | 620,055 |
| Akshay Vaishnaw President of R&D, Director | Apr 16, 2026 | Sale | −12,246 | $49.57 | $607.03K | 630,542 |
| Vikas Sinha Chief Financial Officer | Apr 16, 2026 | Sale | −10,410 | $49.57 | $516.02K | 619,856 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −857 | $47.86 | $41.02K | 98,645 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −200 | $48.48 | $9.70K | 98,445 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sale(10b5-1 plan) | −7,427 | $46.94 | $348.62K | 99,502 |
| Junlin Ho GENERAL COUNSEL | Feb 17, 2026 | Sale | −9,580 | $46.53 | $445.76K | 241,545 |
| Jing L. Marantz CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sale | −4,157 | $46.53 | $193.43K | 126,012 |
| Caryn Parlavecchio CHRO | Feb 17, 2026 | Sale | −9,035 | $46.53 | $420.40K | 169,087 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 | Sale | −7,989 | $46.53 | $371.73K | 106,929 |
| David Hallal Chief Executive Officer, Director | Feb 9, 2026 | Award | +128,004 | – | – | 1,669,649 |
| Vikas Sinha Chief Financial Officer | Feb 9, 2026 | Award | +47,021 | – | – | 630,266 |
| Jing L. Marantz Chief Medical Officer | Feb 9, 2026 | Award | +34,482 | – | – | 130,169 |
| Akshay Vaishnaw President of R&D, Director | Feb 9, 2026 | Award | +47,021 | – | – | 642,788 |
| Keith Woods Chief Operating Officer | Feb 9, 2026 | Award | +47,021 | – | – | 630,275 |
| Caryn Parlavecchio Chief Human Resources Officer | Feb 9, 2026 | Award | +29,258 | – | – | 178,122 |
| Mo Qatanani Chief Scientific Officer | Feb 9, 2026 | Award | +29,258 | – | – | 114,918 |
| Junlin Ho General Counsel | Feb 9, 2026 | Award | +36,572 | – | – | 251,125 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sale(10b5-1 plan) | −12,779 | $46.85 | $598.70K | 85,660 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sale(10b5-1 plan) | −2,119 | $45.87 | $97.20K | 98,439 |
| Jing L. Marantz CHIEF MEDICAL OFFICER | Jan 16, 2026 | Sale | −5,798 | $44.48 | $257.90K | 95,687 |
| Caryn Parlavecchio CHRO | Jan 16, 2026 | Sale | −6,600 | $44.48 | $293.57K | 148,864 |
| Junlin Ho GENERAL COUNSEL | Jan 16, 2026 | Sale | −8,016 | $44.48 | $356.55K | 214,553 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 16, 2026 | Sale | −8,406 | $44.48 | $373.90K | 100,558 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +321 | $7.62 | $2.45K | 110,692 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +2,813 | $10.00 | $28.13K | 113,505 |
| Mo Qatanani CHIEF SCIENTIFIC OFFICER | Jan 14, 2026 | Option exercise | +5,893 | $15.75 | $92.81K | 119,398 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Scholar Rock's stock actually held short. Settlement fails (shares not delivered on time) peaked at 177,778 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Katie Peng Director | Oct 1, 2026 | 1,006 | $48.61K | Oct 1, 2026 | RSU |
| Mohammed Qatanani Officer | Jul 6, 2026 | 11,704 | $639.98K | Jul 6, 2026 | Stock Option Exercise |
| Katie Peng Director | Jul 1, 2026 | 5,446 | $298.39K | Jul 1, 2026 | RSU |
| Michael Gilman Director | Jul 1, 2026 | 2,544 | $139.39K | Jul 1, 2026 | RSU |
| Kristina Burow Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| Jeffrey S. Flier Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| Joshua Reed Director | Jul 1, 2026 | 3,053 | $167.27K | Jul 1, 2026 | RSU |
| Mohammed Qatanani Officer | Apr 6, 2026 | 23,408 | $1.17M | Apr 6, 2026 | Stock Option Exercise |
| Mohammed Qatanani Officer | Feb 23, 2026 | 8,484 | $409.95K | Feb 23, 2026 | Restricted Stock Award |
| Mohammed Qatanani Officer | Jan 22, 2026 | 14,898 | $686.05K | Jan 22, 2026 | Restricted Stock Award |
| Katie Peng Director | Dec 16, 2025 | 1,006 | $45.51K | Dec 16, 2025 | RSU |
| Mohammed Qatanani Officer | Dec 4, 2025 | 149,574 | $6.43M | Dec 4, 2025 | Stock Option Exercise |
| Mohammed Qatanani Officer | Sep 22, 2025 | 3,353 | $102.85K | Sep 22, 2025 | Restricted Stock Award |
| Katie Peng Director | Sep 16, 2025 | 1,006 | $32.73K | Sep 16, 2025 | RSU |
| Mohammed Qatanani Officer | Jul 8, 2025 | 24,066 | $853.86K | Jul 8, 2025 | Restricted Stock Award |
See a number that looks wrong?